Baird Downgrades Amgen to Underperform, Raises Price Target to $185

Baird analyst Brian Skorney downgrades Amgen (NASDAQ:AMGN) from Neutral to Underperform and raises the price target from $173 to $185.

Benzinga · 01/31/2020 11:13

Baird analyst Brian Skorney downgrades Amgen (NASDAQ:AMGN) from Neutral to Underperform and raises the price target from $173 to $185.